LISATA THERAPEUTICS, INC. — Form 8-K
Filed July 17, 2026 · analyzed by the 8-K Agent
8-K
— Neutral
significance 28/100
What the filing says
Lisata Therapeutics, Inc. amended its merger agreement with Kuva Labs Inc. (parent) and Kuva Acquisition Corp. (purchaser), dated March 6, 2026. The sole amendment extends the Outside Date from July 17, 2026 to July 21, 2026 — a 4-day extension. No financial terms, deal value, or other material conditions were modified; all other Merger Agreement provisions remain unchanged.
Why this rating
Administrative extension of closing deadline; no financial impact, deal terms unchanged. Routine for deals approaching close. Neutral for company trajectory.
See more from July 17, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.